U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Drug Databases
  3. REMS

Approved Risk Evaluation and Mitigation Strategies (REMS)

Caprelsa (vandetanib)
NDA #022405
REMS last update: 01/05/2024



What is the purpose of the REMS?

The goals of the CAPRELSA REMS Program are to mitigate the serious risks of QT prolongation, Torsades de pointes, and sudden death associated with use of CAPRELSA by:

  1. Educating prescribers on the following:
    1. Serious risks of QT prolongation, Torsades de pointes, and sudden death associated with use of CAPRELSA.
    2. The need to monitor for QT prolongation and electrolyte abnormalities.
    3. Appropriate management of QT prolongation to minimize the occurrence of Torsades de pointes and sudden death associated with use of CAPRELSA.
  2. Informing patients on the following:
    1. Serious risks of QT prolongation, Torsades de pointes, and sudden death associated with use of CAPRELSA.

What do participants need to know?

Below is a general overview of the REMS for all REMS participants (e.g., patients, pharmacies, and healthcare providers). See the application holder(s) REMS Website or the approved REMS materials for more information.

View application holder(s) REMS Website See Disclaimer page regarding links to external sites

What assessment is available to the REMS?

Assessment Plan
REMS assessment plan unavailable for posting at this time.

What updates have been made to the REMS?

Date Summary of change
01/05/2024 Revised to add a Privacy Cookie Opt-out banner to the REMS website
04/13/2023 Modified to:

  1. Update the Patient brochure and REMS website with the new applicant address and logo.
  2. Update the REMS document format.
05/16/2017 Modified to:

  1. Remove the Medication Guide and the communication plan.
  2. Add the Caprelsa REMS Patient Brochure.
  3. Add changes to the REMS Document including updates to the goals and change in ownership.
  4. Include minor clarifying edits to the following REMS materials to accurately explain the enrollment process and prioritize the presentation of risk information: Caprelsa REMS Prescriber Training Slide Deck, Prescriber Training Pamphlet, Prescriber Training Questions, REMS website screen shots, and Pharmacy Enrollment Form.
11/27/2013 Modified to add information about the risk of upper respiratory tract infection to the Medication Guide.
06/22/2011 Modified to:

  1. Add the CAPRELSA (vandetanib) name to the Medication Guide and other REMS materials.
  2. Make editorial changes requested by FDA.
04/06/2011 Approval of the REMS.

Disclaimer: This webpage provides general information about REMS programs to various REMS participants (e.g., patients, pharmacies, and healthcare providers). The summary information provided herein is not comprehensive and may not include all of the information relevant to REMS participants. This webpage does not constitute a replacement, modification, or revision of the approved REMS document, including any appended REMS materials. Refer to the approved REMS document for complete information on the REMS requirements for each approved application.

Back to Top